Introduction to PMDA’s Early Consideration on Driver Mutations
According to the Early Consideration document issued by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on June 17, 2026, PMDA clarified its current thinking regarding the evidence and explanations expected when sponsors claim that a genetic alteration is a “driver mutation” during the development of anti-cancer drugs. The document is intended to support discussions during PMDA consultations and marketing authorization applications, particularly for precision oncology products targeting specific genomic alterations. As an Early Consideration, it reflects PMDA’s current scientific perspective and may evolve as new evidence emerges.
Background: Increasing Importance of Driver Mutations in Oncology Drug Development
PMDA recognizes that certain molecularly targeted anti-cancer drugs have demonstrated remarkable efficacy in patient populations harboring specific genetic abnormalities. In some cases, substantial clinical benefit has enabled regulatory decisions based on early-stage clinical studies rather than traditional Phase III randomized controlled trials using overall survival as the primary endpoint. This trend is particularly relevant for rare molecular subtypes where conducting large confirmatory studies may be impractical.
The concept of driver mutations is also relevant when evaluating orphan drug designation requests, as scientifically justified biomarker-defined subpopulations may not be considered inappropriate “salami slicing” of larger disease populations.
PMDA’s Perspective on Driver Mutations
The document notes that there is no universally accepted definition of a driver mutation. For regulatory purposes, PMDA considers driver mutations to be genetic alterations that possess strong scientific rationale and clinical relevance from a tumor biology perspective.
PMDA emphasizes that driver mutations should not be identified solely based on the presence of a genetic alteration. Rather, the mutation should demonstrate a high degree of oncogene addiction and provide a reasonable basis for predicting clinical efficacy of a targeted therapy. Evidence from early-stage clinical studies should be considered together with biological data.
Importance of Demonstrating a Causal Relationship
A key concept introduced in the document is the distinction between complex multistep carcinogenesis and situations where a specific genetic alteration has a direct causal relationship with cancer development.
PMDA highlights that genetic abnormalities such as ALK fusion genes and ROS1 fusion genes often exhibit strong oncogenic potential and mutual exclusivity, making them representative examples of alterations that may qualify as driver mutations. When a relatively direct relationship exists between a genetic event and tumor development, therapies targeting such alterations may be expected to produce substantial anti-tumor effects.
However, PMDA does not automatically classify such alterations as driver mutations. Sponsors must provide a scientifically justified explanation based on tumor biology and available clinical evidence.
Evidence Expected When Claiming a Driver Mutation
PMDA recommends that sponsors provide comprehensive evidence supporting the biological significance of the proposed driver mutation. Three major areas should be addressed:
1. Expression of the Altered Gene Product
Sponsors should demonstrate that the genetic alteration leads to expression of the corresponding abnormal protein in the targeted cancer type. The rationale is that functional abnormalities of proteins translated from altered genes may contribute to malignant transformation and cancer progression.
2. Functional Role in Cancer Development
Evidence should demonstrate that the genetic alteration contributes directly to oncogenic behavior. Relevant findings may include:
Examples cited by PMDA include studies involving EML4-ALK gene fusions that induced malignant phenotypes and tumor formation in preclinical models.
3. Demonstration of a Direct Causal Relationship
Sponsors should explain whether the genetic alteration alone can drive tumorigenesis independent of other factors.
PMDA highlights the importance of evidence derived from genetically engineered animal models where expression of the target alteration leads directly to tumor formation in relevant tissues. Examples include transgenic mouse models expressing EML4-ALK, ROS1 fusion genes, and HER2 exon 20 insertion mutations that resulted in rapid development of lung tumors.
Considerations for Tissue-Agnostic and Cross-Cancer Development
The document also addresses development programs that span multiple tumor types.
For tissue-agnostic oncology products, PMDA considers it important to understand both:
Rather than relying solely on conventional organ-specific development paradigms, sponsors are encouraged to collect extensive tumor biology data and provide a scientifically robust rationale for the relevance of the driver mutation across multiple cancer types.
Conclusion
This Early Consideration provides greater regulatory clarity regarding how PMDA evaluates claims related to driver mutations in oncology drug development. The agency emphasizes a science-based approach that integrates tumor biology, nonclinical evidence, and early clinical data to justify the classification of a genetic alteration as a driver mutation.
The framework is particularly relevant for precision oncology programs, rare molecular subtypes, orphan drug applications, and tissue-agnostic development strategies. Sponsors are encouraged to engage with PMDA early in development to discuss the adequacy of the supporting evidence and the relevance of proposed driver mutations.
Reference